CAPR Vaults On Study, CRBP Awaits Data In Q4, OASIS A Shot In The Arm For PRTK

Shares of Paratek Pharmaceuticals Inc. (PRTK) rose over 23% in extended trading on Thursday, following positive results from a phase III study of antibiotic Omadacycline in the treatment of acute bacterial skin and skin structure infections.

from RTT - Biotech http://ift.tt/1YwnA62
via IFTTT